No recommended suppliers. I want be here
[1]. K. Papadopoulos, et al. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. VOLUME 16, SUPPLEMENT 1, 100284, DECEMBER 01, 2022.